1
|
Muksinova MD, Narusov OY, Sychev AV, Sharf TV, Masenko VP, Tereshchenko SN, Skvortsov AA. The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart Failure. Kardiologiia 2023; 63:87-92. [PMID: 38156496 DOI: 10.18087/cardio.2023.12.n2362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 02/10/2023] [Indexed: 12/30/2023]
Abstract
Aim To study the effectiveness of a treatment based on monitoring the soluble ST2 receptor (sST2) concentration in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction (LVEF) after acute decompensated heart failure (ADHF).Material and methods The study included 37 patients hospitalized for ADHF with LVEF ≤40% and sST2 concentration ≥37.8 ng/ml at the time of discharge from the hospital. Patients were randomized into two groups: a sST2 monitoring (sST2M) group (19 patients) and a standard therapy (ST) group (18 patients). The follow-up period was 12 months. At baseline, the groups practically did not differ by clinical, functional, laboratory, and instrumental characteristics. For the sST2M group, the goal was reducing the sST2 concentration by >30% of baseline or to <30 ng/ml.Results Therapy in both groups was comparable both in doses and in frequency of administration of basic drugs. However, the diuretic therapy was more frequently adjusted in the sST2M group (3.0 [1.0; 4.0] vs. 1.0 [0; 3.0] adjustments per patient, p = 0.047), which required more visits to the clinic (7.0 [6.0; 9.0] vs. 6.0 [6.0; 6.0] visits per patient, p=0.024). In the sST2M group at 6 months, the sST2 concentration was decreased by 43.3% (p=0.001), and 13 patients (72.2%) achieved the goal. In the ST group, the sST2 concentration was decreased by 38.5% (p=0.001), and 11 patients (68.8%) reached the target values. After 12 months, the downward trend continued in both groups. In both groups, the NT-proBNP concentration decreased: in the sST2M group by 27.7% (p=0.014), and in the ST group by 31.9% (p = 0.006). By the 12th month, the decrease remained only in the sST2M group. Only the sST2M group had an increase in LVEF (+28.5%, p=0.003), a decrease in left ventricular end-systolic volume (LVESV) (-12.0%, p=0.017), and a decrease in left atrial volume (-13.4%, p=0.045); at 12 months, LVEF remained increased (26%, p=0.006), and LA volume remained decreased (-14.3%, p=0.028). Quality of life and results of 6-minute walk test (6MWT) improved in both groups. For 6 months of treatment, the sST2M group had a significantly lower incidence of composite endpoints (CEP, cardiovascular death and decompensation/hospitalization due to HF), 26.3% (5 events) of the sST2M group compared to the ST group, 83.3% (15 events) (p=0.029), primarily due to a lower incidence of decompensated HF. For 12 months of follow-up, the incidence of CEP in the ST group was 122.2% (22 events), and 47.4% (9 events) in the sST2M group (p=0.035).Conclusions The tactics of sST2 monitoring used in the treatment of "high-risk" HFrEF patients (with high sST2 concentrations) is associated with increased LVEF, improved functional status of patients, a beneficial effect on LV remodeling, and decreased incidence of CEP.
Collapse
Affiliation(s)
- M D Muksinova
- Chazov National Medical Research Center of Cardiology
| | - O Yu Narusov
- Chazov National Medical Research Center of Cardiology
| | - A V Sychev
- Chazov National Medical Research Center of Cardiology
| | - T V Sharf
- Chazov National Medical Research Center of Cardiology
| | - V P Masenko
- Chazov National Medical Research Center of Cardiology
| | | | - A A Skvortsov
- Chazov National Medical Research Center of Cardiology
| |
Collapse
|
2
|
Orlov FI, Ansheles AA, Nasonova SN, Saidova MA, Zhirov IV, Stepanova EA, Suvorina MY, Shoshina AA, Tereshchenko SN, Sergienko VB. [Difficulties in differential diagnosis of the AL- and ATTR-cardiac amyloidosis. Case report]. TERAPEVT ARKH 2023; 95:789-795. [PMID: 38158923 DOI: 10.26442/00403660.2023.09.202376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Indexed: 01/03/2024]
Abstract
The article presents a clinical case describing a complex differential diagnosis of cardiac amyloidosis types and verification of the diagnosis of AL-amyloidosis.
Collapse
Affiliation(s)
- F I Orlov
- Chazov National Medical Research Center of Cardiology
| | - A A Ansheles
- Chazov National Medical Research Center of Cardiology
| | - S N Nasonova
- Chazov National Medical Research Center of Cardiology
| | - M A Saidova
- Chazov National Medical Research Center of Cardiology
| | - I V Zhirov
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - E A Stepanova
- Russian Medical Academy of Continuous Professional Education
| | | | - A A Shoshina
- Chazov National Medical Research Center of Cardiology
| | | | - V B Sergienko
- Chazov National Medical Research Center of Cardiology
| |
Collapse
|
3
|
Nedogoda SV, Tereshchenko SN, Zhirov IV, Salasyuk AS, Barykina IN, Lutova VO, Popova EA. [A clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure in the entire spectrum of left ventricular ejection fraction in the Russian Federation]. TERAPEVT ARKH 2023; 95:782-788. [PMID: 38158921 DOI: 10.26442/00403660.2023.09.202369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 11/04/2023] [Indexed: 01/03/2024]
Abstract
AIM To estimate the cost-effectiveness of dapagliflozin across the range of ejection fraction in patients with heart failure (HF) in Russian Federation. MATERIALS AND METHODS Cost-effectiveness model was developed for estimate the use of dapagliflozin as part of standard therapy in patients with HF regardless of ejection fraction is unknown. The calculation of costs was carried out in a mathematical model adapted to the conditions of Russian healthcare system by using Russian costs inputs and patient population characteristics. RESULTS In the model, dapagliflozin therapy yielded a mean of 0.209 additional life-years compared with standard of care in 10 years horizon. The incremental cost of 1 additional life-year was 665,715 RUB, which does not exceed the threshold of willingness to pay 2,235,202 RUB. CONCLUSION Thus, the intensification of chronic HF therapy with dapagliflozin is cost effective. The use of dapagliflozin in a cohort of 1000 target patients over 10 years will avoid 146 hospitalizations and 39 emergency visits due to HF, as well as prevent 32 deaths from cardiovascular diseases.
Collapse
Affiliation(s)
| | - S N Tereshchenko
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - I V Zhirov
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | | | | | | | | |
Collapse
|
4
|
Reitblat OM, Airapetian AA, Lazareva NV, Mezhonov EM, Sorokin EV, Prints IS, Blankova ZN, Svirida ON, Ageev FT, Zhirov IV, Tereshchenko SN, Boytsov SA. [Creation of registers as one of the mechanisms for improving medical care for patients with chronic heart failure. Problem state]. TERAPEVT ARKH 2023; 95:739-745. [PMID: 38158915 DOI: 10.26442/00403660.2023.09.202370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 07/21/2021] [Indexed: 01/03/2024]
Abstract
The annual mortality of patients with clinically pronounced symptoms of chronic heart failure in the Russian Federation reaches 26-29%, i.e., from 880 to 986 thousand patients with heart failure die in the country in one year, which is comparable to the population of a large city. Providing care for patients with heart failure places a heavy burden on the country's health care system, making a significant contribution to mortality rates, hospitalization rates, including readmissions, which in turn requires considerable costs. The article presents an overview of registry studies that are devoted to assessing the effectiveness of diagnostics, the completeness of examinations, as well as the adequacy of ongoing drug treatment.
Collapse
Affiliation(s)
- O M Reitblat
- Tyumen State Medical University
- Regional Clinical Hospital №1
| | | | - N V Lazareva
- Chazov National Medical Research Center of Cardiology
| | - E M Mezhonov
- Tyumen State Medical University
- Regional Clinical Hospital №1
| | - E V Sorokin
- Chazov National Medical Research Center of Cardiology
| | | | - Z N Blankova
- Chazov National Medical Research Center of Cardiology
| | - O N Svirida
- Chazov National Medical Research Center of Cardiology
| | - F T Ageev
- Chazov National Medical Research Center of Cardiology
| | - I V Zhirov
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - S N Tereshchenko
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - S A Boytsov
- Chazov National Medical Research Center of Cardiology
| |
Collapse
|
5
|
Zhirov IV, Safronova NV, Tereshchenko SN. [Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review]. TERAPEVT ARKH 2023; 95:802-809. [PMID: 38158925 DOI: 10.26442/00403660.2023.09.202400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 11/04/2023] [Indexed: 01/03/2024]
Abstract
Heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction are associated with significant morbidity and mortality, as well as growing economic burden. This review describes recent studies on the use of sacubitril/valsartan in heart failure patients with mildly reduced or preserved ejection fraction.
Collapse
Affiliation(s)
- I V Zhirov
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - N V Safronova
- Chazov National Medical Research Center of Cardiology
| | | |
Collapse
|
6
|
Syrkhaeva AA, Nasonova SN, Zhirov IV, Khalilova UA, Shirkin AV, Shariya MA, Tereshchenko SN. [Possibilities of instrumental determination of volemic status in patients with acute decompensation of chronic heart failure]. TERAPEVT ARKH 2023; 95:769-775. [PMID: 38158920 DOI: 10.26442/00403660.2023.09.202375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 11/04/2023] [Indexed: 01/03/2024]
Abstract
AIM To evaluate and compare the accuracy of volemic status determination by remote dielectric sensing with computed tomography (CT) in patients with acute decompensated heart failure. MATERIALS AND METHODS In 28 patients volemic status was determined by ReDS (remote dielectric sensing), chest computed tomography (CCT), and chest X-ray twice during hospitalization (the day of admission and the day of discharge from the hospital). The ReDS measurements were then compared with CT data using software that allows the use of semi-automated tools to determine mean lung density (MLD). MLD results from Hounsfield Units [HU] were then converted to fluid levels (FU%), allowing them to be compared with ReDS values. In addition, to assess the effect of physical activity on the dynamics of pulmonary stasis there was performed 6-minute walk test (6MWT) followed by determination of volumic status by ReDS method. RESULTS Correlation analysis revealed an average direct significant correlation (r=+0,5; p=0.001) between the CCT and ReDS data. Hypervolemia indexes according to the CCT revealed statistically significant decrease in the dynamics, which was also reflected in the ReDS index decrease. Lung fluid content according to ReDS averaged 38.2±4.6% on admission, and 34.5±3.9% on discharge (p=0.005). According to CT scan of the CCT, MLD at admission was 23.03±3.9%, at discharge 19.6±3.3% (p=0.003). The positive dynamics of the study methods was also reflected in the positive dynamics of NT-proBNP, which decreased by 46%. In the analysis of ReDS data before and after exercise, there was an increase in ReDS value after the performed 6MWT and it was 35.09±3.9% compared with the initial value of 34.5±3.9%. A strong direct significant correlation (r=+0.7; p=0.0001) was found between the ReDS before and after 6MWT at discharge.
Collapse
Affiliation(s)
- A A Syrkhaeva
- Chazov National Medical Research Center of Cardiology
| | - S N Nasonova
- Chazov National Medical Research Center of Cardiology
| | - I V Zhirov
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - U A Khalilova
- People's Friendship University of Russia (RUDN University)
| | - A V Shirkin
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - M A Shariya
- Chazov National Medical Research Center of Cardiology
- Sechenov First Moscow State Medical University (Sechenov University)
| | | |
Collapse
|
7
|
Saipudinova KM, Uskach TM, Shariya MА, Ustyuzhanin DV, Dobrovolskaya SV, Tereshchenko SN. [Effect of dapagliflozin on the dynamics of magnetic resonance imaging in patients with heart failure and atrial fibrillation]. TERAPEVT ARKH 2023; 95:776-781. [PMID: 38158922 DOI: 10.26442/00403660.2023.09.202368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Indexed: 01/03/2024]
Abstract
AIM To determine the effect of dapagliflozin therapy on myocardial remodeling and fibrosis according to magnetic resonance imaging (MRI) with contrast in patients with chronic heart failure (CHF) and atrial fibrillation (AF). MATERIALS AND METHODS In the group of 22 patients with a combination of CHF and AF we analyzed the dynamics of remodeling parameters and assessed myocardial fibrosis during 6-month therapy with dapagliflozin according to cardiac MRI with contrast. RESULTS After 6 months of dapagliflozin therapy there was a statistically significant increase in LVEF (27 [23-32]-32 [26.5-36.5] p-0.04) and a tendency to decrease volume and linear dimensions of LV, LP. There was no progression of myocardial fibrosis according to the results of cardiac MRI with contrast in patients with HFrFV and AF. CONCLUSIONS Dapagliflozin therapy in patients with HFrEF and AF led to favorable myocardial remodeling changes.
Collapse
Affiliation(s)
| | - T M Uskach
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - M А Shariya
- Chazov National Medical Research Center of Cardiology
- Sechenov First Moscow State Medical University (Sechenov University)
| | | | | | | |
Collapse
|
8
|
Safiullina AA, Uskach TM, Saipudinova KM, Tereshchenko SN, Chazova IE. [Heart failure and obesity]. TERAPEVT ARKH 2022; 94:1115-1121. [PMID: 36286764 DOI: 10.26442/00403660.2022.09.201837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Indexed: 06/16/2023]
Abstract
Obesity is an independent predictor of cardiovascular diseases (CVD), including heart failure (HF). Nevertheless, numerous studies have shown that patients with CVD who are overweight and slightly obese have a better short-term and moderate prognosis than thinner patients with CVD. This phenomenon has been called the obesity paradox. Understanding the obesity paradox is important in patients with HF, given the high prevalence of obesity in patients with HF. The article presents an overview of clinical studies devoted to the study of obesity as a risk factor for HF, the pathogenesis of HF in obesity, and highlights the issues of the obesity paradox and the treatment of obesity in this category of patients.
Collapse
Affiliation(s)
| | - T M Uskach
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | | | - S N Tereshchenko
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
| | - I E Chazova
- Chazov National Medical Research Center of Cardiology
| |
Collapse
|
9
|
Dobrovolskaya SV, Saidova MA, Safiullina AA, Uskach TM, Tereshchenko SN. [Evaluation of the effectiveness of the chronic heart failure therapy using the device cardiac contractility modulation according to the new non-invasive method of the myocardium work analysis]. Kardiologiia 2021; 61:31-40. [PMID: 35057719 DOI: 10.18087/cardio.2021.12.n1849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Accepted: 10/29/2021] [Indexed: 06/14/2023]
Abstract
Aim To analyze echocardiographic parameters that reflect left ventricular (LV) myocardial contractility, using a novel method for evaluation of myocardial performance in patients with chronic heart failure (CHF) and atrial fibrillation (AF) during heart contractility modulation (HCM).Material and methods Standard echocardiographic parameters and indexes of myocardial strain and work were analyzed for 66 patients (52 men and 14 women; median age, 60 [54; 66] years). 36 patients had paroxysmal AF and 30 patients had permanent AF. All patients had CHF with a duration of 17 [4; 60] months; duration of AF was 12 [6; 36] months. At baseline, the left ventricular ejection fraction (LV EF) was 33 [27; 37] %.Results After one year of HCM, LV EF significantly increased from 33 [27; 37] to 38 [33; 44] % (р=0.001). Also, there were improvements in the myocardial global longitudinal strain (from -6.00 [ - 8; - 4] to -8 [ - 10; - 6] %; р=0.001) and parameters of myocardial work, including the global work efficiency (from 74 [65; 79] to 80 [73; 87] mm Hg%; р=0.001), global constructive work (from 699 [516; 940] to 882 [714; 1242] mm Hg%; р=0.001), and global myocardial work index (from 460 [339; 723] to 668 [497; 943] mm Hg%; р=0.001). A segmentary analysis of LV work parameters showed positive changes in the myocardial constructive work in the area of the interventricular septal apical segment (at baseline, 844 [614; 1224]; after HCM, 1027 [800; 1520] mm Hg%; р=0.05) and the medium segment of the LV anteroseptal wall (at baseline, 593 [312; 1000]; after HCM, 877 [494; 1145] mm Hg%; р=0.05).Conclusion This method for analysis of the myocardial work provides a more detailed examination of LV structural and functional remodeling and mechanisms for its effects on the LV contractile function in patients with CHF. This method is promising and merits further study in various clinical situations.
Collapse
Affiliation(s)
| | - M A Saidova
- National Medical Research Center of Cardiology, Moscow, Russia
| | - A A Safiullina
- National Medical Research Center of Cardiology, Moscow, Russia
| | - T M Uskach
- National Medical Research Center of Cardiology, Moscow, Russia
| | | |
Collapse
|
10
|
Safiullina AA, Uskach TM, Dobrovolskaya SV, Saidova MA, Makeev MI, Tereshchenko SN. Reverse remodeling against the background of cardiac contractility modulation therapy in patients with heart failure and atrial fibrillation. Cardiovasc Ther Prev 2021. [DOI: 10.15829/1728-8800-2022-2948] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Aim. To study myocardial remodeling in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) against the background of cardiac contractility modulation (CCM) therapy.Material and methods. In a group of 100 patients with HFrEF and AF, transthoracic echocardiography was performed before CCM device implantation and after 2, 6 and 12 months. All patients received longterm optimal medical therapy for HF before surgery.Results. Against the background of CCM therapy, there was a significant increase in left ventricular (LV) ejection fraction, a decrease in LV volume and linear dimensions, a decrease in left atrial volume in patients with coronary and non-coronary HFrEF, with an initial LVEF < and >35%, and also regardless of AF type.Conclusion. CCM therapy in patients with HFrEF and AF led to favorable myocardial remodeling changes. Further study of CCM effect on echocardiographic parameters in randomized clinical trials is needed.
Collapse
Affiliation(s)
| | - T. M. Uskach
- National Medical Research Center of Cardiology;
Russian Medical Academy of Continuous Professional Education
| | | | | | | | - S. N. Tereshchenko
- National Medical Research Center of Cardiology;
Russian Medical Academy of Continuous Professional Education
| |
Collapse
|
11
|
Tarlovskaya EI, Arutyunov AG, Konradi AO, Lopatin YM, Rebrov AP, Tereshchenko SN, Chesnikova AI, Hayrapetyan HG, Babin AP, Bakulin IG, Bakulina NV, Balykova LA, Blagonravova AS, Boldina MV, Vaisberg AR, Galyavich AS, Gomonova VV, Grigorieva NY, Gubareva IV, Demko IV, Evzerikhina AV, Zharkov AV, Kamilova UK, Kim ZF, Kuznetsova TY, Lareva NV, Makarova EV, Malchikova SV, Nedogoda SV, Petrova MM, Pochinka IG, Protasov KV, Protsenko DN, Ruzanau DY, Sayganov SA, Sarybaev AS, Selezneva NM, Sugraliev AB, Fomin IV, Khlynova OV, Chizhova OY, Shaposhnik II, Shсukarev DA, Abdrahmanova AK, Avetisian SA, Avoyan HG, Azarian KK, Aimakhanova GT, Ayipova DA, Akunov AC, Alieva MK, Aparkina AV, Aruslanova OR, Ashina EY, Badina OY, Barisheva OY, Batchayeva AS, Bitieva AM, Bikhteyev IU, Borodulina NA, Bragin MV, Budu AM, Burygina LA, Bykova GA, Vagapova KR, Varlamova DD, Vezikova NN, Verbitskaya EA, Vilkova OE, Vinnikova EA, Vustina VV, Gаlova EA, Genkel VV, Gorshenina EI, Gostishev RV, Grigorieva EV, Gubareva EY, Dabylova GM, Demchenko AI, Dolgikh OY, Duyshobayev MY, Evdokimov DS, Egorova KE, Ermilova AN, Zheldybayeva AE, Zarechnova NV, Zimina YD, Ivanova SY, Ivanchenko EY, Ilina MV, Kazakovtseva MV, Kazymova EV, Kalinina YS, Kamardina NA, Karachenova AM, Karetnikov IA, Karoli NA, Karpov OV, Karsiev MK, Кaskaeva DS, Kasymova KF, Kerimbekova ZB, Kerimova AS, Kim ES, Kiseleva NV, Klimenko DA, Klimova AV, Kovalishena OV, Kolmakova EV, Kolchinskaya TP, Kolyadich MI, Kondriakova OV, Konoval MP, Konstantinov DY, Konstantinova EA, Kordukova VA, Koroleva EV, Kraposhina AY, Kriukova TV, Kuznetsova AS, Kuzmina TY, Kuzmichev KV, Kulchoroeva CK, Kuprina TV, Kouranova IM, Kurenkova LV, Kurchugina NY, Kushubakova NA, Levankova VI, Levin MЕ, Lyubavina NA, Magdeyeva NA, Mazalov KV, Majseenko VI, Makarova AS, Maripov AM, Marusina AA, Melnikov ES, Moiseenko NB, Muradova FN, Muradyan RG, Myshak AO, Nikitina NM, Ogurlieva BB, Odegova AA, Omarova YM, Omurzakova NA, Ospanova SO, Pahomova EV, Petrov LD, Plastinina SS, Pogrebetskaya VA, Polyakov DS, Ponomarenko EV, Popova LL, Prokofeva NA, Pudova IA, Rakov NA, Rakhimov AN, Rozanova NA, Serikbolkyzy S, Simonov AA, Skachkova VV, Soloveva DV, Soloveva IA, Sokhova FM, Subbotin AK, Sukhomlinova IM, Sushilova AG, Tagayeva DR, Titojkina YV, Tikhonova EP, Tokmin DS, Tolmacheva AA, Torgunakova MS, Trenogina KV, Trostianetckaia NA, Trofimov DA, Tulichev AA, Tursunova AT, Ulanova ND, Fatenkov OV, Fedorishina OV, Fil TS, Fomina IY, Fominova IS, Frolova IA, Tsvinger SM, Tsoma VV, Cholponbaeva MB, Chudinovskikh TI, Shevchenko OA, Sheshina TV, Shishkina EA, Shishkov KY, Sherbakov SY, Yausheva EA, Musaelian SN, Belenkov YN, Arutyunov GP. Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»). ACTA ACUST UNITED AC 2021; 61:20-32. [PMID: 34713782 DOI: 10.18087/cardio.2021.9.n1680] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Accepted: 05/28/2021] [Indexed: 11/18/2022]
Abstract
Aim To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features). The register territory included 7 countries: the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan. The registry design: a closed, multicenter registry with two nonoverlapping arms (outpatient arm and in-patient arm). The registry scheduled 6 visits, 3 in-person visits during the acute period and 3 virtual visits (telephone calls) at 3, 6, and 12 mos. Patient enrollment started on June 29, 2020 and was completed on October 29, 2020. The registry completion is scheduled for October 29, 2022. The registry ID: ClinicalTrials.gov: NCT04492384. In this fragment of the study of registry data, the work group analyzed the effect of therapy for comorbidities at baseline on severity and outcomes of the novel coronavirus infection. The study population included only the patients who took their medicines on a regular basis while the comparison population consisted of noncompliant patients (irregular drug intake or not taking drugs at all despite indications for the treatment).Results The analysis of the ACTIVE registry database included 5808 patients. The vast majority of patients with COVID-19 had comorbidities with prevalence of cardiovascular diseases. Medicines used for the treatment of COVID-19 comorbidities influenced the course of the infectious disease in different ways. A lower risk of fatal outcome was associated with the statin treatment in patients with ischemic heart disease (IHD); with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists and with beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation; with oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD; with oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM); and with long-acting insulins in patients with type 1 DM. A higher risk of fatal outcome was associated with the spironolactone treatment in patients with CHF and with inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD).Conclusion In the epoch of COVID-19 pandemic, a lower risk of severe course of the coronavirus infection was observed for patients with chronic noninfectious comorbidities highly compliant with the base treatment of the comorbidity.
Collapse
Affiliation(s)
- E I Tarlovskaya
- Eurasian Association of Therapists, Moscow; Privolzhsky Research Medical University, Nizhny Novgorod
| | - A G Arutyunov
- Eurasian Association of Therapists, Moscow; N. I. Pirogov Russian National Research Medical University, Moscow
| | - A O Konradi
- V. A. Almazov National Medical Research Center, St. Peterburg
| | | | - A P Rebrov
- V. I. Razumovsky Saratov State Medical University, Saratov
| | | | | | - H G Hayrapetyan
- Erebouni Medical Center, Cardiology and Cardiac Surgery Clinic, Erevan
| | - A P Babin
- Nikolae Testemitanu Sate University of Medicine and Pharmacy, Kishinev
| | - I G Bakulin
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - N V Bakulina
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - L A Balykova
- N. P. Ogarev National Research Mordovia State University, Saransk
| | | | - M V Boldina
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - A R Vaisberg
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - A S Galyavich
- Interregional Clinical Diagnostic Center, Kazan; Kazan State Medical University, Kazan
| | - V V Gomonova
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - N Yu Grigorieva
- N. I. Lobachevsky National Research State University of Nizhny Novgorod, Nizhny Novgorod
| | | | - I V Demko
- Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk
| | | | | | - U K Kamilova
- National Specialized Science and Practice Medical Center for Therapy and Medical Rehabilitation, Tashkent
| | - Z F Kim
- Kazan Municipal Clinical Hospital №7, Kazan
| | | | | | - E V Makarova
- Privolzhsky Research Medical University, Nizhny Novgorod
| | | | | | - M M Petrova
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | - I G Pochinka
- Privolzhsky Research Medical University, Nizhny Novgorod; Municipal Clinical Hospital #13 of the Nizhny Novgorod Avtozavodsky District, Nizhny Novgorod
| | - K V Protasov
- Irkutsk State Medical Academy of Postgraduate Education, Branch of the Russian Medical Academy of Continuing Professional Education, Irkutsk
| | | | | | - S A Sayganov
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - A S Sarybaev
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | - N M Selezneva
- N. P. Ogarev National Research Mordovia State University, Saransk
| | - A B Sugraliev
- S. D. Asfendiyarov Kazakh National Medical University, Alma-Ata
| | - I V Fomin
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - O V Khlynova
- Akademician E. A. Vagner Perm State Medical University, Perm
| | - O Yu Chizhova
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | | | | | - A K Abdrahmanova
- Kazakh Medical University of Continuous Education, Alma-Ata; I. Zhekenova Municipal Clinical Hospital for Infectious Diseases, Alma-Ata
| | - S A Avetisian
- Erebouni Medical Center, Cardiology and Cardiac Surgery Clinic, Erevan
| | - H G Avoyan
- Erebouni Medical Center, Cardiology and Cardiac Surgery Clinic, Erevan
| | - K K Azarian
- Erebouni Medical Center, Cardiology and Cardiac Surgery Clinic, Erevan
| | - G T Aimakhanova
- S. D. Asfendiyarov Kazakh National Medical University, Alma-Ata
| | - D A Ayipova
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | - A Ch Akunov
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | - M K Alieva
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - A V Aparkina
- V. I. Razumovsky Saratov State Medical University, Saratov
| | | | - E Yu Ashina
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - O Yu Badina
- Privolzhsky District Medical Center, Nizhny Novgorod
| | | | - A S Batchayeva
- N. I. Pirogov Russian National Research Medical University, Moscow
| | - A M Bitieva
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - I U Bikhteyev
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | | | - M V Bragin
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - A M Budu
- Municipal Clinical Hospital №1, Kishinev
| | - L A Burygina
- P. B. Gannushkin Psychiatric Clinical Hospital №4, Moscow
| | - G A Bykova
- Akademician E. A. Vagner Perm State Medical University, Perm
| | - K R Vagapova
- Polyclinic №1 at the Administrative Department of the President of the Russian Federation, Moscow
| | | | | | - E A Verbitskaya
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | - O E Vilkova
- N. I. Lobachevsky National Research State University of Nizhny Novgorod, Nizhny Novgorod
| | - E A Vinnikova
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | | | - E A Gаlova
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - V V Genkel
- South Ural State Medical University, Chelyabinsk
| | - E I Gorshenina
- N. P. Ogarev National Research Mordovia State University, Saransk
| | | | - E V Grigorieva
- V. I. Razumovsky Saratov State Medical University, Saratov
| | | | - G M Dabylova
- S. D. Asfendiyarov Kazakh National Medical University, Alma-Ata
| | | | | | - M Y Duyshobayev
- S. D. Asfendiyarov Kazakh National Medical University, Alma-Ata
| | - D S Evdokimov
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - K E Egorova
- V. A Baranov Karelia Republic Hospital, Petrozavodsk
| | - A N Ermilova
- Eurasian Association of Therapists, Moscow; V. P. Serbsky National Medical Research Center of Psychiatry and Narcology, Moscow
| | | | | | - Yu D Zimina
- Municipal Clinical Hospital №25, Novosibirsk
| | | | | | - M V Ilina
- Kirovsk Inter-District Hospital, outpatient department, Kirovsk
| | | | - E V Kazymova
- Clinical Hospital at the Samara Station "Russian Railways Medicine", Samara
| | - Yu S Kalinina
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | - N A Kamardina
- Privolzhsky District Medical Center, Nizhny Novgorod
| | | | - I A Karetnikov
- Irkutsk Regional Clinical Hospital, recipient of the "Badge of Honor" award, Irkutsk
| | - N A Karoli
- V. I. Razumovsky Saratov State Medical University, Saratov
| | - O V Karpov
- P. B. Gannushkin Psychiatric Clinical Hospital #4, Moscow
| | - M Kh Karsiev
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - D S Кaskaeva
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | - K F Kasymova
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | - Zh B Kerimbekova
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | | | - E S Kim
- Kazan State Medical University, Kazan; Kazan Municipal Clinical Hospital №7, Kazan
| | - N V Kiseleva
- Privolzhsky Research Medical University, Nizhny Novgorod
| | | | - A V Klimova
- N. I. Pirogov Russian National Research Medical University, Moscow; Municipal Polyclinic №134, Moscow
| | | | - E V Kolmakova
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | | | - M I Kolyadich
- South Ural State Medical University, Chelyabinsk; Chelyabinsk Municipal Clinical Hospital №1, Chelyabinsk
| | | | - M P Konoval
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | | | | | - V A Kordukova
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - E V Koroleva
- Municipal Clinical Hospital №5 of the Nizhny Novgorod Nizhegorodsky District, Nizhny Novgorod
| | - A Yu Kraposhina
- Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk; Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | | | | | - T Yu Kuzmina
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | - K V Kuzmichev
- Municipal Clinical Hospital №13 of the Nizhny Novgorod Avtozavodsky District, Nizhny Novgorod
| | - Ch K Kulchoroeva
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | | | | | | | | | - N A Kushubakova
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | | | - M Е Levin
- P. B. Gannushkin Psychiatric Clinical Hospital №4, Moscow
| | - N A Lyubavina
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - N A Magdeyeva
- V. I. Razumovsky Saratov State Medical University, Saratov
| | - K V Mazalov
- Privolzhsky District Medical Center, Nizhny Novgorod
| | | | - A S Makarova
- Irkutsk State Medical Academy of Postgraduate Education, Branch of the Russian Medical Academy of Continuing Professional Education, Irkutsk
| | - A M Maripov
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | - A A Marusina
- Kirovsk Inter-District Hospital, outpatient department, Kirovsk
| | - E S Melnikov
- Eurasian Association of Therapists, Moscow; I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - N B Moiseenko
- N. I. Lobachevsky National Research State University of Nizhny Novgorod, Nizhny Novgorod
| | - F N Muradova
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - R G Muradyan
- Global Medical System Clinics and Hospitals, Moscow
| | | | - N M Nikitina
- V. I. Razumovsky Saratov State Medical University, Saratov
| | - B B Ogurlieva
- N. I. Pirogov Russian National Research Medical University, Moscow; Municipal Clinical Hospital №4, Moscow
| | | | - Yu M Omarova
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - N A Omurzakova
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | - Sh O Ospanova
- S. D. Asfendiyarov Kazakh National Medical University, Alma-Ata
| | - E V Pahomova
- GBUZ RK "Republican tuberculosis dispensary", Petrozavodsk
| | | | - S S Plastinina
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - V A Pogrebetskaya
- Municipal Clinical Hospital №38 of the Nizhny Novgorod Nizhegorodsky District, Nizhny Novgorod
| | - D S Polyakov
- Privolzhsky Research Medical University, Nizhny Novgorod
| | | | | | - N A Prokofeva
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - I A Pudova
- Privolzhsky Research Medical University, Nizhny Novgorod; Municipal Polyclinic №4 of the Nizhny Novgorod Kanavinsky District, Nizhny Novgorod
| | - N A Rakov
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - A N Rakhimov
- 21 National Specialized Science and Practice Medical Center for Therapy and Medical Rehabilitation, Tashkent
| | | | - S Serikbolkyzy
- S. D. Asfendiyarov Kazakh National Medical University, Alma-Ata
| | - A A Simonov
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | | | - D V Soloveva
- Privolzhsky Research Medical University, Nizhny Novgorod
| | - I A Soloveva
- Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk; Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | - F M Sokhova
- P. B. Gannushkin Psychiatric Clinical Hospital №4, Moscow
| | - A K Subbotin
- Privolzhsky District Medical Center, Nizhny Novgorod
| | | | - A G Sushilova
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - D R Tagayeva
- National Specialized Science and Practice Medical Center for Therapy and Medical Rehabilitation, Tashkent
| | - Yu V Titojkina
- N. P. Ogarev National Research Mordovia State University, Saransk
| | - E P Tikhonova
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | | | - A A Tolmacheva
- Novosibirsk State Medical University, Novosibirsk; Clinical Consultative and Diagnostic Polyclinic №27, Novosibirsk
| | - M S Torgunakova
- Prof. V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk
| | | | | | - D A Trofimov
- Kazan State Medical University, Kazan; Kazan Municipal Clinical Hospital №7, Kazan
| | - A A Tulichev
- Privolzhsky Research Medical University, Nizhny Novgorod; Municipal Clinical Hospital №3, Nizhny Novgorod
| | - A T Tursunova
- S. D. Asfendiyarov Kazakh National Medical University, Alma-Ata
| | - N D Ulanova
- Municipal Clinical Hospital #13 of the Nizhny Novgorod Avtozavodsky District, Nizhny Novgorod
| | | | - O V Fedorishina
- Irkutsk State Medical Academy of Postgraduate Education, Branch of the Russian Medical Academy of Continuing Professional Education, Irkutsk
| | - T S Fil
- I. I. Mechnikov North-Western State Medical University, St. Petersburg
| | - I Yu Fomina
- Privolzhsky Research Medical University, Nizhny Novgorod; Municipal Polyclinic #1, Nizhny Novgorod
| | - I S Fominova
- N. P. Ogarev National Research Mordovia State University, Saransk
| | - I A Frolova
- Privolzhsky District Medical Center, Nizhny Novgorod
| | | | - V V Tsoma
- Volgograd State Medical University, Volgograd
| | - M B Cholponbaeva
- M. M. Mirrakhimov National Center of Cardiology and Therapy, Bishkek
| | | | | | - T V Sheshina
- N. I. Lobachevsky National Research State University of Nizhny Novgorod, Nizhny Novgorod
| | - E A Shishkina
- Akademician E. A. Vagner Perm State Medical University, Perm
| | | | - S Yu Sherbakov
- Kazan State Medical Academy, Branch of the Russian Medical Academy of Continuing Professional Education, Kazan
| | - E A Yausheva
- N. P. Ogarev National Research Mordovia State University, Saransk
| | | | - Yu N Belenkov
- The First Moscow state medical University I. M. Sechenov
| | - G P Arutyunov
- Eurasian Association of Therapists, Moscow; N. I. Pirogov Russian National Research Medical University, Moscow
| |
Collapse
|
12
|
Nasonova SN, Lapteva AE, Zhirov IV, Tereshchenko SN, Boytsov SA. [Remote monitoring of patients with heart failure in real clinical practice]. Kardiologiia 2021; 61:76-86. [PMID: 34549697 DOI: 10.18087/cardio.2021.8.n1683] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Accepted: 07/16/2021] [Indexed: 11/18/2022]
Abstract
Prevalence of chronic heart failure (CHF) is continuously growing and is associated with increased incidence of hospitalizations, morbidity and mortality. Furthermore, the increase in the number of rehospitalizations results in greater expenses and worsening of quality of life. In order to decrease the number of unscheduled hospitalizations and the death rate, the outpatient care should be improved, which can be achieved by using telemedical technologies. The aim of this review was collection and analysis of currently available information about the use of telemonitoring for patients with CHF. A systematic search and analysis of reports published from 2010 through 2020 in Web of Science, Scopus, and PubMed/MEDLINE databases was performed.
Collapse
Affiliation(s)
- S N Nasonova
- National Medical Research Center of Cardiology, Moscow, Russia
| | - A E Lapteva
- National Medical Research Center of Cardiology, Moscow, Russia
| | - I V Zhirov
- National Medical Research Center of Cardiology, Moscow, Russia Russian Medical Academy of Continuing Professional Education, Moscow, Russia
| | - S N Tereshchenko
- National Medical Research Center of Cardiology, Moscow, Russia Russian Medical Academy of Continuing Professional Education, Moscow, Russia
| | - S A Boytsov
- National Medical Research Center of Cardiology, Moscow, Russia
| |
Collapse
|
13
|
Kapustina AY, Minushkina LO, Alekhin MN, Selezneva ND, Safaryan VI, Brazhnik VA, Chumakova OS, Evdokimova MA, Galyavich AS, Khasanov NR, Chichkova MA, Kosmacheva ED, Tereshchenko SN, Koziolova NA, Glezer MG, Boeva OI, Konstantinov VO, Zateyshchikov DA. [Left ventricular global function index as a predictor of adverse cardiovascular events in patients with acute coronary syndrome]. Kardiologiia 2021; 61:23-31. [PMID: 34549690 DOI: 10.18087/cardio.2021.8.n1508] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 03/12/2021] [Accepted: 04/15/2021] [Indexed: 11/18/2022]
Abstract
Aim To evaluate the prognostic significance of the left ventricular global function index (LV GFI) in patients with acute coronary syndrome (ACS) using echocardiography (EchoCG).Material and methods The LV GFI is an index that integrates LV cavity volumes, stroke volume, and myocardial volume. This study included 2169 patients with ACS (1340 (61.8%) men) aged 64.1±12.6 years from two observational multicenter studies, ORACLE I and ORACLE II. 1800 (83 %) cases were associated with increased concentrations of myocardial injury markers, including 826 (38.1 %) cases of ST segment elevation myocardial infarction (MI). The observation was started on the 10th day of clinical condition stabilization and lasted for one year. EchoCG was performed with evaluation of LV GFI, which was calculated as a ratio of LV stroke volume to LV global volume. The LV global volume was calculated as a sum of mean LV cavity volume (LV end-diastolic volume + LV end-systolic volume / 2) and LV myocardial volume.Results The main outcome of the study was all-cause death (n=193); recurrent coronary complications (n=253) were analyzed separately. The only EchoCG parameter indicating an adverse outcome during the one-year follow-up was a LV GFI decrease to below 22.6 % with a sensitivity of 72 % and a specificity of 60% (area under the curve, AUC=0.63). A LV GFI <22.6 % was an independent predictor of all-cause death (p=0.019) along with age (p=0.0001), history of MI (p=0.034), and presence of heart failure (HF) (p=0.044), diabetes mellitus (p=0.012), and peripheral atherosclerosis (p=0.001). The LV GFI <22.6 %, (p=0.044), heart rate upon discharge from the hospital (p=0.050), history of MI (p=0.006), presence of HF (p=0.014), and peripheral atherosclerosis (p=0.001) were also independent predictors for recurrent coronary complications. Decreased LV GFI was associated with the risk of fatal outcomes independent of the LV ejection fraction at baseline.Conclusion In patients with ACS, the left ventricular global function index is an independent predictor for all-cause death and recurrent coronary complications and may be used for risk stratification.
Collapse
Affiliation(s)
- A Yu Kapustina
- Central State Medical Academy of Department of Presidential Affairs, Moscow; Central Clinical Hospital With Outpatient Clinic, Moscow
| | - L O Minushkina
- Central State Medical Academy of Department of Presidential Affairs, Moscow
| | - M N Alekhin
- Central State Medical Academy of Department of Presidential Affairs, Moscow; Central Clinical Hospital With Outpatient Clinic, Moscow
| | - N D Selezneva
- Central State Medical Academy of Department of Presidential Affairs, Moscow; City Clinical Hospital No. 51, Moscow
| | | | - V A Brazhnik
- Central State Medical Academy of Department of Presidential Affairs, Moscow; City Clinical Hospital No. 51, Moscow
| | - O S Chumakova
- Central State Medical Academy of Department of Presidential Affairs, Moscow
| | | | | | | | - M A Chichkova
- Astrakhan State Medical University "Ministry of Health of Russia, Astrakhan
| | | | - S N Tereshchenko
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow
| | | | - M G Glezer
- First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow
| | - O I Boeva
- 1Stavropol State Medical University, Stavropol
| | - V O Konstantinov
- North-West State Medical University named after I.I. Mechnikov, St. Peterburg
| | - D A Zateyshchikov
- Central State Medical Academy of Department of Presidential Affairs, Moscow; City Clinical Hospital No. 51, Moscow
| |
Collapse
|
14
|
Uskach TM, Safiullina AA, Sharapova YS, Amanatova VA, Petrukhina AA, Makeev MI, Tereshchenko SN. Four-year follow-up of a patient with mixed cardiomyopathy and an implanted cardiac contractility modulation device: a case report. Cardiovasc Ther Prev 2021. [DOI: 10.15829/1728-8800-2021-2811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
The article presents a case report of a 28-year-old male patient with mixed dilated cardiomyopathy: myocardial noncompaction and chemotherapy-related cardiotoxicity, which led to severe heart failure (HF). With optimal drug therapy, the patient was implanted with a cardiac contractility modulation device in order to improve exercise tolerance, quality of life and relieve HF symptoms. Complex therapy has led to significant clinical and echocardiographic improvement. This case demonstrates a 4-year follow-up of a patient with a reduced left ventricular ejection fraction and an implanted cardiac contractility modulation device, whose condition, after several severe HF decompensations, was stabilized.
Collapse
Affiliation(s)
- T. M. Uskach
- National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
| | | | | | | | | | | | - S. N. Tereshchenko
- National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
| |
Collapse
|
15
|
Amanatova VA, Safiullina AA, Uskach TM, Ansheles AA, Sergienko VB, Tereshchenko SN. Possibilities of Evaluating the Dynamics of Left Ventricular Perfusion and Contractility in Patients with Chronic Heart Failure after Implantation of a Heart Contractility Modulator Using Perfusion Single-Photon Emission Computed Tomography. Racionalʹnaâ farmakoterapiâ v kardiologii 2021. [DOI: 10.20996/1819-6446-2021-04-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Perfusion scintigraphy and single-photon emission tomography of the myocardium are promising methods for complex assessment of the state of the left ventricle myocardium in patients with chronic heart failure. These methods of nuclear cardiology can be performed in patients with reduced renal function, as well as the presence of implanted devices such as implantable cardioverters-defibrillators, resynchronizing devices and cardiac modulating therapy, which is their undeniable advantage. The reproducibility of the method is ensured bu fully automated calculation of parameters of myocardial perfusion and contractility. To date, there are no data in the literature on the use of nuclear cardiology methods as an imaging technique in patients with cardiac contractility modulation devises. This paper describes the current possibilities and prospects of nuclear medicine methods in patients with chronic heart failure after implantation of a heart contractility modulator.
Collapse
Affiliation(s)
| | | | - T. M. Uskach
- National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
| | | | | | - S. N. Tereshchenko
- National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
| |
Collapse
|
16
|
Arutyunov GP, Tarlovskaya EI, Arutyunov AG, Belenkov YN, Konradi AO, Lopatin YM, Tereshchenko SN, Rebrov AP, Chesnikova AI, Fomin IV, Grigorieva NU, Boldina VM, Vaisberg AR, Blagonravova AS, Makarova EV, Shaposhnik II, Kuznetsova TY, Malchikova SV, Protsenko DN, Evzerikhina AV, Petrova MM, Demko IV, Saphonov DV, Hayrapetyan HG, Galyavich AS, Kim ZF, Sugraliev AB, Nedogoda SV, Tsoma VV, Sayganov SA, Gomonova VV, Gubareva IV, Sarybaev AS, Ruzanau DY, Majseenko VI, Babin AP, Kamilova UK, Koroleva EV, Vilkova OE, Fomina IY, Pudova IA, Soloveva DV, Doshchannikov DA, Kiseleva NV, Zelyaeva NV, Kouranova IM, Pogrebetskaya VA, Muradova FN, Badina OY, Kovalishena OV, Gаlova AE, Plastinina SS, Grigorovich MS, Lyubavina NA, Vezikova NN, Levankova VI, Ivanova SY, Ermilova AN, Muradyan RG, Gostishev RV, Tikhonova EP, Kuzmina TY, Soloveva IA, Kraposhina AY, Kolyadich MI, Kolchinskaya TP, Genkel VV, Kuznetsova AS, Kazakovtseva MV, Odegova AA, Chudinovskikh TI, Baramzina SV, Rozanova NA, Kerimova AS, Krivosheina NA, Chukhlova SY, Levchenko AA, Avoyan HG, Azarian KK, Musaelian SN, Avetisian SA, Levin ME, Karpov OV, Sokhova FM, Burygina LA, Sheshina TV, Tiurin AA, Dolgikh OY, Kazymova EV, Konstantinov DY, Chumakova OA, Kondriakova OV, Shishkov KY, Fil ST, Prokofeva NA, Konoval MP, Simonov AA, Bitieva AM, Trostianetckaia NA, Cholponbaeva MB, Kerimbekova ZB, Duyshobayev MY, Akunov AC, Kushubakova NA, Melnikov ES, Kim ES, Sherbakov SY, Trofimov DA, Evdokimov DS, Ayipova DA, Duvanov IA, Abdrahmanova AK, Aimakhanova GT, Ospanova SO, Gaukhar MD, Tursunova AT, Kaskaeva DS, Tulichev AA, Ashina EY, Kordukova VA, Barisheva OY, Egorova KE, Varlamova DD, Kuprina TV, Pahomova EV, Kurchugina NY, Frolova IA, Mazalov KV, Subbotin AK, Kamardina NA, Zarechnova NV, Mamutova EM, Smirnova LA, Klimova AV, Shakhgildyan LD, Tokmin DS, Tupitsin DI, Kriukova TV, Polyakov DS, Karoli NA, Grigorieva EV, Magdeyeva NA, Aparkina AV, Nikitina NM, Petrov LD, Budu AM, Rasulova ZD, Tagayeva DR, Fatenkov OV, Gubareva EY, Demchenko AI, Klimenko DA, Omarova YV, Serikbolkyzy S, Zheldybayeva AE. [International register "Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients (ACTIV SARS-CoV-2)"]. Kardiologiia 2021; 60:30-34. [PMID: 33487147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 01/11/2021] [Indexed: 06/12/2023]
|
17
|
Arutyunov GP, Tarlovskaya EI, Arutyunov AG, Belenkov YN, Konradi AO, Lopatin YM, Tereshchenko SN, Rebrov AP, Chesnikova AI, Fomin IV, Grigorieva NU, Boldina VM, Vaisberg AR, Blagonravova AS, Makarova EV, Shaposhnik II, Kuznetsova TY, Malchikova SV, Protsenko DN, Evzerikhina AV, Petrova MM, Demko IV, Saphonov DV, Hayrapetyan HG, Galyavich AS, Kim ZF, Sugraliev AB, Nedogoda SV, Tsoma VV, Sayganov SA, Gomonova VV, Gubareva IV, Sarybaev AS, Ruzanau DY, Majseenko VI, Babin AP, Kamilova UK, Koroleva EV, Vilkova OE, Fomina IY, Pudova IA, Soloveva DV, Doshchannikov DA, Kiseleva NV, Zelyaeva NV, Kouranova IM, Pogrebetskaya VA, Muradova FN, Omarova YV, Badina OY, Kovalishena OV, Gаlova AE, Plastinina SS, Grigorovich MS, Lyubavina NA, Vezikova NN, Levankova VI, Ivanova SY, Ermilova AN, Muradyan RG, Gostishev RV, Tikhonova EP, Kuzmina TY, Soloveva IA, Kraposhina AY, Kolyadich MI, Kolchinskaya TP, Genkel VV, Kuznetsova AS, Kazakovtseva MV, Odegova AA, Chudinovskikh TI, Baramzina SV, Rozanova NA, Kerimova AS, Krivosheina NA, Chukhlova SY, Levchenko AA, Avoyan HG, Azarian KK, Musaelian SN, Avetisian SA, Levin ME, Karpov OV, Sokhova FM, Burygina LA, Sheshina TV, Tiurin AA, Dolgikh OY, Kazymova EV, Konstantinov DY, Chumakova OA, Kondriakova OV, Shishkov KY, Fil ST, Prokofeva NA, Konoval MP, Simonov AA, Bitieva AM, Trostianetckaia NA, Cholponbaeva MB, Kerimbekova ZB, Duyshobayev MY, Akunov AC, Kushubakova NA, Melnikov ES, Kim ES, Sherbakov SY, Trofimov DA, Evdokimov DS, Ayipova DA, Duvanov IA, Abdrahmanova AK, Aimakhanova GT, Ospanova SO, Dabylova GM, Tursunova AT, Kaskaeva DS, Tulichev AA, Ashina EY, Kordukova VA, Barisheva OY, Egorova KE, Varlamova DD, Kuprina TV, Pahomova EV, Kurchugina NY, Frolova IA, Mazalov KV, Subbotin AK, Kamardina NA, Zarechnova NV, Mamutova EM, Smirnova LA, Klimova AV, Shakhgildyan LD, Tokmin DS, Tupitsin DI, Kriukova TV, Polyakov DS, Karoli NA, Grigorieva EV, Magdeyeva NA, Aparkina AV, Nikitina NM, Petrov LD, Budu AM, Rasulova ZD, Tagayeva DR, Fatenkov OV, Gubareva EY, Demchenko AI, Klimenko DA, Serikbolkyzy S, Zheldybayeva AE. International register “Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients (ACTIV SARS-CoV-2)”. Kardiologiia 2020. [DOI: 10.18087/cardio.2020.11.n1398] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
18
|
Uskach TM, Safiullina AA, Sapel'nikov OV, Amanatova VA, Nikolaeva OA, Grishin IR, Nazarov BM, Tereshchenko SN. [Modulation of cardiac contractility in patients with chronic heart failure and atrial fibrillation]. TERAPEVT ARKH 2020; 92:8-14. [PMID: 33346425 DOI: 10.26442/00403660.2020.09.000598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Accepted: 10/13/2020] [Indexed: 01/08/2023]
Abstract
AIM to evaluate the effectiveness of cardiac contractility modulation (MSS) in patients with chronic heart failure (CHF) and atrial fibrillation (AF). MATERIALS AND METHODS The following studies were performed in 40 patients with CHF and AF before implantation of the MSS device and after 2 and 6 months of follow-up: 12-channel ECG, transthoracic EchoCG, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), daily ECG monitoring, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ). All patients received long-term optimal drug therapy for CHF before surgery. RESULTS The results obtained indicate a statistically significant positive effect of the use of MSS in patients with CHF and AF on LV FV, the functional class of CHF, and levels of NT-proBNP regardless of the etiology of CHF. CONCLUSION The use of MSS may be promising for the treatment of heart failure in patients with CHF and AF.
Collapse
Affiliation(s)
- T M Uskach
- National Medical Research Center for Cardiology.,Russian Medical Academy of Continuous Professional Education
| | | | | | | | | | - I R Grishin
- National Medical Research Center for Cardiology
| | | | - S N Tereshchenko
- National Medical Research Center for Cardiology.,Russian Medical Academy of Continuous Professional Education
| |
Collapse
|
19
|
Zateyshchikov DA, Minushkina LO, Brazhnik VA, Galyavich AS, Khasanov NR, Chichkova MA, Kosmacheva ED, Tereshchenko SN, Koziolova NA, Glezer MG, Boeva OI, Khorolets EV, Konstantinov VO. [Changes in the management of patients with acute coronary syndrome - have the disease outcomes changed?]. ACTA ACUST UNITED AC 2020; 60:30-37. [PMID: 33131472 DOI: 10.18087/cardio.2020.9.n1172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 06/29/2020] [Indexed: 11/18/2022]
Abstract
Aim To analyze results of changing the management tactics in patients with acute coronary syndrome (ACS) in clinical practice from 2004 through 2018 expressed as improvement in prognosis.Material and methods Results of two observational studies were analyzed: ORACLE I (2004-2007), which included 1193 patients with ACS (mean age, 61.1±11.69 years; men, 63.3 %) and ORACLE II (2014-2017), which included 1652 patients from 4 vascular centers (mean age, 64.61±12.67 years; men, 62.3 %).Results Patients included into the ORACLE II study in 2014 were significantly older and the proportion of patients with diabetes mellitus was greater than in the ORACLE I study (14.7 and 22.6 %, respectively). After matching the groups by major clinical characteristics, it was found that introducing the invasive management tactics for ACS patients was associated with a reduced rate of all-cause death (from 8.2 to 6.1 % for one year), a tendency towards decreased number of coronary death cases (from 5.6 to 4.0 %), and a decrease in risk of recurrent coronary complications (from 17.4 to 7.7 %).Conclusion Implementing the vascular program statistically significantly decreased the total death rate for at least one-year observation in comparable patient groups.
Collapse
Affiliation(s)
- D A Zateyshchikov
- City Clinical Hospital №51 of State Healthcare Agency Moscow, Moscow
| | - L O Minushkina
- Central State Medical Academy of Department of Presidential Affairs, Moscow
| | - V A Brazhnik
- City Clinical Hospital №51 of State Healthcare Agency Moscow, Moscow
| | | | | | - M A Chichkova
- Central State Medical Academy of Department of Presidential Affairs, Moscow
| | | | - S N Tereshchenko
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow
| | | | - M G Glezer
- First Moscow State Medical University named after I.M. Sechenov, Moscow
| | - O I Boeva
- Stavropol State Medical University, Stavropol
| | | | - V O Konstantinov
- North-West State Medical University named after I.I. Mechnikov, St-Peterburg
| |
Collapse
|
20
|
Shlyakhto YV, Arutyunov GP, Belenkov YN, Tarlovskaya EI, Konradi AO, Panchenko EP, Yavelov IS, Tereshchenko SN, Ardashev AV, Arutyunov AG, Grigorieva NY, Dzhunusbekova GA, Drapkina OM, Koziolova NA, Komarov AL, Kropacheva ES, Malchikova SV, Mitkovskaya NP, Orlova YA, Petrova MM, Rebrov AP, Sisakian H, Skibitsky VV, Sugraliyev AB, Fomin IV, Chesnikova AI, Shaposhnik II, Zhelyakov EG, Kanorskii SG, Kolotsey LV, Snezhitskiy VA. [Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts' Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association]. ACTA ACUST UNITED AC 2020; 60:1180. [PMID: 32720611 DOI: 10.18087/cardio.2020.6.n1180] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Accepted: 05/25/2020] [Indexed: 12/12/2022]
Abstract
This article discusses relevant aspects in the treatment of patients with COVID-19. Up-to-date information about principles for administration of statins, antithrombotics, and antiarrhythmics is presented. The authors addressed in detail specific features of reversing heart rhythm disorders in patients with coronavirus infection and the interaction of antiarrhythmic and antiviral drugs. Recommendations are provided for outpatient and inpatient antithrombotic therapy for patients with COVID-19. Issues of antithrombotic and antiviral drug interaction are discussed.
Collapse
Affiliation(s)
- Ye V Shlyakhto
- Almazov National Medical Research Centre of Ministry of Healthcare of Russia, Saint- Petersburg
| | - G P Arutyunov
- Pirogov Russian National Research Medical University, Moscow
| | - Yu N Belenkov
- First Moscow state medical University I. M. Sechenov, Moscow
| | | | - A O Konradi
- National research medical center V. A. Almazov of Ministry of Healthcare of Russia, Saint-Petersburg
| | - E P Panchenko
- National Medical Research Center of Cardiology, Moscow
| | - I S Yavelov
- National Medical Research Center for Therapy and Preventive Medicine, Moscow
| | | | | | - A G Arutyunov
- Pirogov Russian National Research Medical University, Moscow
| | | | | | - O M Drapkina
- National Center for Therapy and Preventive Medicine, Moscow
| | - N A Koziolova
- State funded educational institution of the highest education "E.A. Wagner Perm State Medical University" Public Health Ministry of Russian Federation, Perm
| | - A L Komarov
- Department of clinical problems of atherothrombosis "NMIC cardiology" of the Ministry of health of the Russian Federation, Moscow
| | | | - S V Malchikova
- Kirov State Medical University Kirov State Medical University, Kirov
| | - N P Mitkovskaya
- Cardiology and internal diseases of BSMU, Republic of Belarus, Minsk
| | | | - M M Petrova
- Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Krasnoyarsk
| | - A P Rebrov
- Saratov State Medical University named after V.I. Razumovsky, Saratov
| | - H Sisakian
- Yerevan State Medical University, Yerevan
| | | | - A B Sugraliyev
- Asfendiyarov Kazakh National Medical University, Alma-Atyu
| | - I V Fomin
- Volga Research Medical University, Nizhny Novgorod
| | | | | | | | - S G Kanorskii
- Kuban State Medical University of the Ministry of Healthcare of the Russian Federation, Krasnodar
| | | | | |
Collapse
|
21
|
Uskach TM, Safiullina AA, Makeev MI, Saidova MA, Shariya MA, Ustyuzhanin DV, Zhirov IV, Tereshchenko SN. [The effect of angiotensin receptors and neprilysin inhibitors on myocardial remodeling in patients with chronic heart failure and atrial fibrillation]. ACTA ACUST UNITED AC 2019; 59:64-72. [PMID: 31876463 DOI: 10.18087/cardio.n815] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 10/02/2019] [Accepted: 10/07/2019] [Indexed: 11/18/2022]
Abstract
AIM To evaluate the effect of angiotensin-neprilysin receptor inhibitors on myocardial remodeling in patients with chronic heart failure and atrial fibrillation. MATERIALS AND METHODS We studied dynamics of the parameters of ultrasound structural and functional parameters of the left atrium and left ventricle of the heart was during 3-month therapy with sacubitryl-valsartan in a group of 15 patients with a combination of chronic heart failure due to dilated and paroxysmal paroxysmal forms of atrial fibrillation. RESULTS Showed a statistically significant positive effect of the use of angiotensin receptors and neprilysin inhibitors on the parameters of remodeling of the left atrium (according to transthoracic and transesophageal echocardiography), left ventricle, as well as levels of natriuretic peptides ANP and NT-pro-BNP. CONCLUSION The use of ARNI may be promising in terms of treatment and prevention of AF in patients with heart failure.
Collapse
Affiliation(s)
- T M Uskach
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| | - A A Safiullina
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| | - M I Makeev
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| | - M A Saidova
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| | - M A Shariya
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| | - D V Ustyuzhanin
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| | - I V Zhirov
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| | - S N Tereshchenko
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation
| |
Collapse
|
22
|
Zhirov IV, Baulina NM, Nasonova SN, Osmak GZ, Matveyeva NA, Mindzaev DR, Favorova OO, Tereshchenko SN. [Full - transcriptome analysis of miRNA expression in mononuclear cells in patients with acute decompensation of chronic heart failure of various etiologies]. TERAPEVT ARKH 2019; 91:62-67. [PMID: 32598816 DOI: 10.26442/00403660.2019.09.000294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Indexed: 11/22/2022]
Abstract
It is known that micro RNAs are an important regulatory element in the pathogenesis of many diseases, including cardiovascular diseases. Different levels of expression of these molecules in various pathologies makes miRNA a potential diagnostic and prognostic biomarker. AIM Analysis of miRNA expression levels in mononuclear blood cells (MBC) of patients with acute decompensation f chronic heart failure (CHF) of various etiologies and evaluation of the possibility of their use as a biological marker. MATERIALS AND METHODS 7 male patients with acute decompensation of CHF with a reduced ejection fraction (EF), NYHA functional class II-IV (FC) according to NYHA [mean (M) EF 29.2%, standard deviation (SD) 13.27%] in age 38 to 65 years old [median (Me) 58 years]. In 3 patients, heart failure developed as a result of dilated cardiomyopathy (DCMP), in 4 patients - against the background of post - infarction cardiosclerosis of the ischemic nature [group of patients with coronary heart disease (CHD)]. The control group - 5 age - matched (from 41 to 57 years old, Me 49 years old) healthy male volunteers. A complete transcript analysis of miRNA expression in MNCs was performed for all patients and healthy volunteers. RESULTS Differentially expressed miRNAs were determined in patients with CHF (regardless of etiology) compared with healthy individuals: miR-182, miR-144, miR-183, miR-486-5p, miR-143 (log2FC >1, FDR p - value.
Collapse
Affiliation(s)
- I V Zhirov
- Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology.,Russian Medical Academy of Continuing Professional Education
| | - N M Baulina
- Institute of Experimental Cardiology, National Medical Research Center of Cardiology
| | - S N Nasonova
- Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology
| | - G Z Osmak
- Institute of Experimental Cardiology, National Medical Research Center of Cardiology
| | - N A Matveyeva
- Institute of Experimental Cardiology, National Medical Research Center of Cardiology
| | - D R Mindzaev
- Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology
| | - O O Favorova
- Institute of Experimental Cardiology, National Medical Research Center of Cardiology
| | - S N Tereshchenko
- Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology.,Russian Medical Academy of Continuing Professional Education
| |
Collapse
|
23
|
Nasonova SN, Zhirov IV, Ledyakhova MV, Sharf TV, Bosykh EG, Masenko VP, Tereshchenko SN. Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure. TERAPEVT ARKH 2019; 91:67-73. [PMID: 31094479 DOI: 10.26442/00403660.2019.04.000168] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
AIM To study the possibilities of previously diagnosing acute renal damage in patients with acute decompensation of chronic heart failure with reduced systolic function using biomarkers of acute renal injury. MATERIALS AND METHODS The study included 60 patients (62.0±11.1 years) with HADS (BNP >500 pg/ml) and a reduced left ventricular ejection fraction (LV 27.05% [23.25; 32.75], c FC III-IV NYHA). The level of creatinine, urea, uric acid, albumin in serum was determined in all patients, as well as a number of biomarkers: lipocalin associated with neutrophil gelatinase (NGAL) and cystatin C (CysC) in serum; kidney damage molecule-1 (KIM-1) and angiotensinogen (AGT) in the urine. RESULTS AKI is determined based on changes in serum creatinine concentration or diuresis value. The results obtained indicate a high specificity and sensitivity of the use of biomarkers for the diagnosis of AKI in patients with ADHF. NGAL AUC - 0.833 (p<0.001), Se - 82.8%, Sp - 4.2%. CysC AUC - 0.823 (p<0.001), Se - 79.3%, Sp - 74.2%. KIM-1 AUC - 0.782 (p<0.001), Se - 75.9%, Sp - 74.2%. AGT AUC - 0.829 (p<0.001), Se - 82.8%, Sp - 77.4%. In a multifactorial regression analysis, it was found that with NGAL greater than 157.35 ng/ml, the risk of AKI increases 13.1 times (95% CI 1.365-126.431), with an increase in KIM-1, the risk of the development of AKI increases 20.6 times (95% CI 1.802-235.524), and with an increase in AGT more than 14.31 leng/ml, the risk of AKI increases 32.8 times (95% CI 2.752-390.110). CONCLUSION Acute kidney injury develops in 48.3% of patients hospitalized with acute decompensation of chronic heart failure. Patients with acute decompensation of chronic heart failure and AKI have significantly higher serum NGAL and CysC, KIM-1 and AGT values in the urine compared with patients without impairing renal function. These biomarkers can serve both for the early diagnosis of acute kidney damage and the prediction of AKI in patients with acute decompensation of chronic heart failure.
Collapse
Affiliation(s)
- S N Nasonova
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - I V Zhirov
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia.,Russian Medical Academy Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - M V Ledyakhova
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - T V Sharf
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - E G Bosykh
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - V P Masenko
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - S N Tereshchenko
- National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia.,Russian Medical Academy Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia
| |
Collapse
|
24
|
Ledyakhova MV, Nasonova SN, Zhirov IV, Yarovaya EB, Uskach TM, Masenko VP, Tereshchenko SN. [Neutrophil gelatinase-associated lipocalin for early diagnosis of acute kidney injury in patients with acute decompensated heart failure]. Kardiologiia 2019:44-50. [PMID: 30362428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
BACKGROUND the incidence of acute kidney injury (AKI) is high in patients with acute decompensated heart failure (ADHF) and is linked with increased morbidity and mortality rates. Predictive biomarkers of AKI could allow improve outcomes in AKI. PURPOSE to evaluate the value of serum neutrophil gelatinase-associated lipocalin (NGAL) concentrations for early diagnosis of AKI in patients with ADHF with left ventricular (LV) systolic function. METHODS we enrolled 60 men (average age was 62.0±11.1 years) hospitalized with ADHF with reduced LV systolic function (LV ejection fraction (LVEF).
Collapse
Affiliation(s)
| | | | - I V Zhirov
- National Medical Research Center for Cardiology
| | - E B Yarovaya
- Federal State Budgetary Educational Institution of Higher Education, "M. V. Lomonosov Moscow State University"
| | - T M Uskach
- National Medical Research Center for Cardiology
| | - V P Masenko
- National Medical Research Center for Cardiology
| | | |
Collapse
|
25
|
Uskach TM, Tereshchenko SN, Pavlenko TA, Zhirov IV, Sapelnikov OV, Akchurin RS. Possibilities and perspectives of using cardiac contractility modulation in patients with chronic heart failure and atrial fibrillation. ACTA ACUST UNITED AC 2019; 59:4-14. [PMID: 30853008 DOI: 10.18087/cardio.2616] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 03/05/2019] [Indexed: 11/18/2022]
Abstract
Heart failure is one of the main health care problems all over the world. Although, there are many drugs with proven effectiveness and hi-tech devices, there is a continuous process of searching new possibilities in heart failure prophylaxis going on because of huge economic burden and impact on life quality. Developing of atrial fibrillation in heart failure patients increases the risks of hospitalization and all-cause mortality. Appearance of new Optimizer Smart® system of cardiac contractility modulation is a perspective way of treatment in patients with heart failure and atrial fibrillation, who are not a candidate or have not got a good result from cardiac resynchronization therapy (CRT).
Collapse
Affiliation(s)
- T M Uskach
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation..
| | | | | | | | | | | |
Collapse
|
26
|
Protasov VN, Narusov OY, Skvortsov AA, Protasova DE, Kuznetsova TV, Petrukhina AA, Masenko VP, Tereshchenko SN. Multimarker Approach in Risk Stratification of Patients with Decompensated Heart Failure. ACTA ACUST UNITED AC 2019; 59:53-64. [PMID: 30706839 DOI: 10.18087/cardio.2637] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 01/31/2019] [Indexed: 11/18/2022]
Abstract
PURPOSE to study prognostic value of various biomarkers and their combinations in patients who survived decompensation of chronic heart failure. MATERIALS AND METHODS Patients (n=159) who were hospitalized with diagnosis of heart failure (HF) decompensation were included in a prospective single-center study. Examination on admission and the day of hospital discharge, included measurement of concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), copeptin, soluble suppression of tumorigenicity 2 (sST2), kopetin, neutrophil gelatinase-associated lipocalin (NGAL), and galectin-3. Te combined primary endpoint comprised cardiovascular (CV) death, frst hospitalization because of HF heart failure decompensation, episodes of HF deterioration which required additional i/v diuretics, and CV death with successful resuscitation. RESULTS During one-year follow-up 56 pts (35.2%) reached the combined primary endpoint. Tere were 78 (49.1%) cardiovascular events. During hospitalization, patients with the decompensation of heart failure experienced a decrease of sST2, NT-proBNP, galectin-3, kopetin, hsTnT and an insignifcant increase of NGAL. ROC analysis identifed signifcant relation between concentrations of NT-proBNP, sST2, copeptin and, to a lesser degree, hsTnT, determined at hospital discharge, and risk of combined primary endpoint during 1-year follow-up: area under the curve (AUC) was 0.733 [95% CI 0.645-0.820], p<0.0001, 0.772 [95% CI 0.688-0.856], p<0.0001, 0.735 [95% CI 0.640-0.830], p<0.0001, and 0.659 [95% CI 0.553-0.764], p=0.005, respectively. Patients who during hospitalization did not achieve cut-off values of NT-proBNP ≤1696 rg/ml, sST2≤37.8 hg/ml, copeptin≤28.31 rmol/L and hsTnT≤28.37 rg/ml, had higher risk of reaching adverse events during 1 year; OR and 95% CI were 2.96 [1.61, 5.42] p<0.0001, 4.31 [2.34, 7.93] p<0.0001, 3.06 [1.59, 5.89] and 2.19 [2.12, 4.27]), respectively. According to Cox regression analysis, risk of the combined primary end point was the highest in patients with 3 or more elevated markers (OR = 6.6 [3.584, 12.158], p<0.0001), average in patients with 2 elevated markers (OR = 1.123 [0.51, 2.48]), p=0.7), and the lowest in patients with no markers increase or increase of only one marker (OR = 0.11 [0.049, 0.241], p<0.0001). In the Kaplan-Mayer survival analysis all three groups were statistically different. In order to identify the most prognostically strong model, a reclassifcation analysis was performed. According to this analysis, the combination of sST2 and NT-proBNP concentrations determined at hospital discharge, exceeded one NT-proBNP (reclassifcation = -8.1%). At the same time, predictive value of only sST2 just insignifcantly less than value of sST2 and NT-proBNP combination (reclassifcation = -1.9%). CONCLUSION Patients with three and more elevated markers at hospital discharge have high risk of adverse events. Te biggest prognostic value has combination of sST2 and NT-proBNP concentrations. In order to determine the long-term prognosis of a patient with HF decompensation, it is sufcient to measure concentrations of sST2 and NT-proBNP at hospital discharge. Alternatively, it is possible to limit to sST2 only, which is just insignifcantly inferior to the sST2 and NT-proBNP combination. Patients with concentrations of sST2 ≥37.8 hg/ml and NT-proBNP ≥1696 rg/ml at hospital discharge have maximal 1year risk of death due to recurrent HF decompensation.
Collapse
Affiliation(s)
- V N Protasov
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation.
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Skvortsov AA, Narusov OY, Muksinova MD, Protasov VN, Protasova DE, Kuznetsova TV, Masenko VP, Tereshchenko SN. Clinical significance of serial biomarkers activity determination after acute heart failure decompensation: sST2 NT-proBNP role during long-term follow-up. ACTA ACUST UNITED AC 2018; 58:27-41. [PMID: 30625106 DOI: 10.18087/cardio.2634] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Accepted: 12/26/2018] [Indexed: 11/18/2022]
Abstract
AIM Monitoring of concentrations of modern biomarkers to evaluate the efficacy of long‑term treatment of patients after acute decompensated HF (ADHF). MATERIALS AND METHODS The study included 100 patients with severe decompensated FC II-IV CHF and LV EF <40 % due to IHD, DCMP or AH. At discharge from the hospital, patients were divided into groups of low (NT‑proBNP<1400 pg / ml) (control, n=30) and high (NT‑proBNP≥1400 pg / ml) risk (n=70). Patients at high risk were randomized to two treatment groups, a group of NT‑proBNP monitoring (NPM) (n=35) and a group of standard therapy (n=35). At the end of the study, noncompliant patients were isolated from these two groups into a separate group (n=10). The aim of the treatment was decreasing the NT‑proBNP concentration to less than 1000 pg / ml and / or ≥50 % of the baseline level. In addition to the soluble suppression of tumorigenicity 2 (sST2) receptor, concentrations of copeptin, neutrophil gelatinase associated lipocalin (NCAL), galectin 3, and high‑sensitivity troponin T were measured at discharge from the hospital (baseline) and at three and 6 months of treatment. RESULTS The strongest correlations were found between changes in concentrations (Δ%) of NT‑proBNP, copeptin, and sST2 and changes in CHF FC, 6‑min walk distance, CCS, quality of life, LV EF, and Е / Е' (р<0.001). The incidence of cardiovascular events was directly related with the degree of decrease and / or increase in biomarker concentration. Patients of the NPM group had the lowest risk of adverse clinical outcome upon a decrease in NT‑proBNP <988.5 pg / ml at 6 months of treatment or > 50 % of the baseline level at discharge from the hospital. For these patients, the mean Δ% was 60.7±8.5 % for NT‑proBNP, 34.03±17.6 % for sST2, and 32.41±8.8 % for copeptin [OR at 95 % CI 0.08 (0.02-0.36), р <0.0001]. A significant increase in the risk for cardiovascular events was observed only at a considerable increase in NT‑proBNP >50 % [OR at 95 % CI 3.8 (1.13-13.0), р=0.03], and the highest incidence of cardiovascular events was observed in the group of noncompliant patients (110 %). Besides NT‑proBNP, to significantly decrease the risk of cardiovascular events, it was necessary to achieve a decrease in sST2 concentration to less than 30 ng / ml or by more than 24.9 % (Δ%) at the end of followup [ОR (95 % CI: 0.1 (0.02-0.5), р=0.004]. CONCLUSION Among the modern biomarkers, changes in NT‑proBNP, sST2, and copeptin concentrations most accurately reflect changes in the clinical and functional status, quality of life, and EchoCG parameters in HF patients during long‑term monitoring. The lowest risk for adverse clinical outcomes was observed in post‑decompensation patients with a decrease in NT‑proBNP <988.5 pg / ml after 6 months of treatment or ≥50 % of baseline upon discharge from the hospital. The sST2 concentration has to be reduced by more than 24.9 % of baseline and less than 30 ng / ml in the course of long‑term treatment after decompensated HF.
Collapse
Affiliation(s)
- A A Skvortsov
- FSBO National Medical research center of cardiology of the Ministry of healthcare of the Russian Federation.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Tereshchenko SN, Zhirov IV, Petrukhina AA. [Clinical and demographic characteristics of an outpatient Russian population with chronic heart failure at the time of enrollment in the QUALIFY registry for evaluating consistency with clinical guidelines on drug therapy]. Kardiologiia 2018; 57:324-330. [PMID: 29276898 DOI: 10.18087/cardio.2363] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND Chronic heart failure is the most common condition in patients with cardiovascular diseases. Therefore, evaluating consistency of doctor's recommendations with guidelines on drug therapy is a relevant issue. AIM To evaluate consistency of doctor's recommendations with guidelines on drug therapy for CHF. MATERIALS AND METHODS The study presents enrollment visit data for the Russian part of the international prospective registry, QUALIFY. The study included 404 outpatient patients with CHF between February, 2013 through June, 2014. Consistency with guidelines for drug therapy was evaluated for 5 drug classes, including ACE inhibitors (ACEI), β-blockers (BB), angiotensin receptor antagonists (ARA), mineralocorticoid receptor antagonists (MRA), and ivabradine. RESULTS On the whole, the consistency was good in 64.9% of cases, moderate in 27.7% of cases, and poor in 7.4% of cases. Proportions of patients who received a target dose of a medicine and a dose ≥50% of the target dose were low, 21.5% and 62.3% for ACEI; 15% and 50.8% for BB; 20.3% and 39.8% for ARA; and 23.4% and 78.7% for ivabradine, respectively. These values, except for BB, were lower for patients with late hospitalization (hospitalization ≥6 months vs.
Collapse
Affiliation(s)
- S N Tereshchenko
- Federal State Budgetary Institution, "Russian Cardiology Science and Production Center" of the Ministry of Health of the Russian Federation
| | - I V Zhirov
- Federal State Budgetary Institution, "Russian Cardiology Science and Production Center" of the Ministry of Health of the Russian Federation
| | - A A Petrukhina
- Federal State Budgetary Institution, "Russian Cardiology Science and Production Center" of the Ministry of Health of the Russian Federation
| |
Collapse
|
29
|
Averkova AO, Brazhnik VA, Rogozhina AA, Evdokimova MA, Koroleva OS, Sizgunov DS, Zubova EA, Karmanchikova EA, Galyavich AS, Hasanov NR, Ivantsov EN, Magamedkerimova FA, Chichkov YM, Chichkova MA, Kovalenko NV, Tereshchenko SN, Minushkina LO, Koziolova NA, Glezer MG, Boeva OI, Khorolets EV, Konstantinov VO, Zateyshchikov DA. [Family History of Cardiovascular Disease in Patients With Early Development of Acute Coronary Syndrome]. Kardiologiia 2018:12-17. [PMID: 30131037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
UNLABELLED The aim of the study was to analyze clinical features of patients with premature acute coronary syndrome (ACS) in relation to family history of cardiovascular disease (CVD) and familial hypercholesterolemia (FH). MATERIALS AND METHODS Of 2832 patients included in ORACUL 1 and ORACUL 2 multicenter observational trials 512 pts who developed premature ACS (≤55 years for men, ≤60 years for women) and had known family history and LDL level were selected for this study. Of these patients 297 had positive family history (51 with FH, 246 no FH), 215 had negative family history. RESULTS Among patients with positive family history there were more women (31 vs 20.9 %), while among patients with negative family history there were more men (79.1 vs 69 %). The fact of regular alcohol consumption was significantly more frequently observed among patients with positive family history but without FH, compared to patients with positive family history with FH (69.6 vs 47.1 %). Women with positive family history smoked more frequently than females with negative family history (51.1 vs 31.1 %). Among patients with negative family history compared with patients with positive family history there were more people who at admission had hyperglycemia exceeding 11.1 mmol / l (10.3 vs 4.4 %). Multiple vessel disease and coronary calcinosis were present in 73.2 and 24.7 %, respectively, of patients with positive family history, and in 56.9 and 9.8 %, respectively, of those with negative family history. Among patients with positive family history multivessel disease was more frequent in the subgroup with FH, while coronary calcinosis was more frequent in the subgroup without FH. CONCLUSION Thus, premature development of ACS might be associated not only with genetic factors but also with family history ("inheritance") of adverse habits. Herewith coronary calcinosis is more prevalent in patients with FH.
Collapse
Affiliation(s)
- A O Averkova
- Central State Medical Academy, President Management Department RF
| | - V A Brazhnik
- Central State Medical Academy, President Management Department RF
| | - A A Rogozhina
- Central State Medical Academy, President Management Department RF
| | | | - O S Koroleva
- Central State Medical Academy, President Management Department RF
| | | | | | | | - A S Galyavich
- Federal State Budget Educational Institution of Higher Education, "Kazan State Medical University" of the Ministry of Health of the Russian Federation
| | - N R Hasanov
- Federal State Budget Educational Institution of Higher Education, "Kazan State Medical University" of the Ministry of Health of the Russian Federation
| | - E N Ivantsov
- Federal State Budget Educational Institution of Higher Education, "Kazan State Medical University" of the Ministry of Health of the Russian Federation
| | - F A Magamedkerimova
- Federal State Budget Educational Institution of Higher Education, "Kazan State Medical University" of the Ministry of Health of the Russian Federation
| | | | | | | | | | - L O Minushkina
- Central State Medical Academy, President Management Department RF
| | - N A Koziolova
- Federal State Budgetary Educational Institution of Higher Education, "Academician E. A. Vagner Perm State Medical Academy" of the Ministry of Health of the Russian Federation
| | - M G Glezer
- Federal State Budgetary Educational Institution of Higher Education "I. M. Sechenov First Moscow State Medical University" of the Ministry of Health of the Russian Federation
| | - O I Boeva
- State Budgetary Educational Institution of Higher Professional Education, "Stavropol State Medical University" of the Ministry of Healthcare
| | - E V Khorolets
- Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation
| | - V O Konstantinov
- State Budgetary Educational Institution of Higher Professional Education, "I. I. Mechnikov North-West State Medical University" of the RF Ministry of Health Care
| | | |
Collapse
|
30
|
Protasov VN, Skvortsov AA, Narusov OY, Protasova DE, Gimadiev RR, Abramov A, Masenko VP, Tereshchenko SN. P6517MicroRNA-21-5p and microRNA-423-5p are predictors for short-term prognosis in patients with acute decompensated heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- V N Protasov
- Russian Cardiology Research and Production Complex, Moscow, Russian Federation
| | - A A Skvortsov
- Russian Cardiology Research and Production Complex, Moscow, Russian Federation
| | - O Y Narusov
- Russian Cardiology Research and Production Complex, Moscow, Russian Federation
| | - D E Protasova
- National Research Center for Preventive Medicine, Moscow, Russian Federation
| | - R R Gimadiev
- Russian Cardiology Research and Production Complex, Moscow, Russian Federation
| | - A Abramov
- Russian Cardiology Research and Production Complex, Moscow, Russian Federation
| | - V P Masenko
- Russian Cardiology Research and Production Complex, Moscow, Russian Federation
| | - S N Tereshchenko
- Russian Cardiology Research and Production Complex, Moscow, Russian Federation
| |
Collapse
|
31
|
Brazhnik VA, Minushkina LO, Evdokimova MA, Galyavich AS, Tereshchenko SN, Koziolova NA, Glezer MG, Yagoda AV, Khorolets EV, Dankovtseva EN, Boeva OI, Konstantinov VO, Zateishchikov DA. [Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3‑Years Follow-up]. Kardiologiia 2018; 58:14-22. [PMID: 30081805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
PURPOSE to analyze possible associations of clinical and genetic factors with development of ischemic stroke after exacerbation of ischemic heart disease (IHD). MATERIALS AND METHODS The Russian multicenter study aimed at assessment of risk of unfavorable outcomes after exacerbation of IHD "Exacerbation of IHD: logical probabilistic ways to course prognostication for optimization of treatment" (meaning of Cyrillic acronym - oracle) was conducted in 16 centers of 7 cities in Russia. We included into the study 1 208 patients with unstable angina and ST-elevation or non-ST-elevation myocardial infarction (MI). Data on outcomes were known for 1 193 patients, 15 patients were lost for follow-up. RESULTS Mean duration of follow-up was 644±14.45 (4-1 995) days. Shortest, longest, and mean time before development of stroke was 22, 1433 and 389±56.6 days after inclusion. Patients with strokes were older, more often had history of IHD prior to index hospitalization, arterial blood pressure level compatible with stage 3 arterial hypertension, less often were smokers, and more often had MI recurrences or repetitive episodes of severe ischemia during the index hospitalization. Patients also more often had documented atrial fibrillation during hospitalization, and lower level of glomerular filtration rate. Of studied genetic markers carriage of A allele of polymorphic marker G (-1082) A of interleukin-10 gene was significantly associated with risk of stroke development. Using linear regression analysis, we constructed a model of estimation of the stroke development risk. Comparison of diagnostic value of different scales for stroke risk assessment showed that area under the curve was 0.656, 0.686, and 0.756 for the GRACE, CHA2DS2‑VASc, and ORACLE scores, respectively.
Collapse
Affiliation(s)
| | - L O Minushkina
- Federal State Budgetary Institution "Educational and Scientific Medical Center" at the Department of Presidential Affairs
| | | | - A S Galyavich
- Federal State Budget Educational Institution of Higher Education, "Kazan State Medical University" of the Ministry of Health of the Russian Federation
| | - S N Tereshchenko
- Federal State Budgetary Institution, "Russian Cardiology Science and Production Center" of the Ministry of Health of the Russian Federation
| | - N A Koziolova
- Federal State Budgetary Educational Institution of Higher Education, "Academician E. A. Vagner Perm State Medical Academy" of the Ministry of Health of the Russian Federation
| | - M G Glezer
- Federal State Budgetary Educational Institution of Higher Education "I. M. Sechenov First Moscow State Medical University" of the Ministry of Health of the Russian Federation
| | - A V Yagoda
- State Budgetary Educational Institution of Higher Professional Education, "Stavropol State Medical University" of the Ministry of Healthcare
| | - E V Khorolets
- Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation
| | | | - O I Boeva
- State Budgetary Educational Institution of Higher Professional Education, "Stavropol State Medical University" of the Ministry of Healthcare
| | - V O Konstantinov
- State Budgetary Educational Institution of Higher Professional Education, "I. I. Mechnikov North-West State Medical University" of the RF Ministry of Health Care
| | | |
Collapse
|
32
|
Lediakhova MV, Nasonova SN, Zhirov IV, Andreevskaya MV, Bogieva RM, Uskach TM, Saidova MA, Masenko VP, Tereshchenko SN. IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. Racionalʹnaâ farmakoterapiâ v kardiologii 2018. [DOI: 10.20996/1819-6446-2018-14-2-176-183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
33
|
Sergienko VB, Tereshchenko SN, Ansheles AA, Zhirov IV, Safiullina AA. NUCLEAR IMAGING IN THE DIAGNOSIS OF CARDIAC AMYLOIDOSIS. Racionalʹnaâ farmakoterapiâ v kardiologii 2018. [DOI: 10.20996/1819-6446-2018-14-1-94-100] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
34
|
Romakina VV, Zhirov IV, Nasonova SN, Zaseeva AV, Kochetov AG, Liang OV, Tereshchenko SN. MicroRNAs as Biomarkers of Cardiovascular Diseases. CARDIO 2018:66-71. [DOI: 10.18087/cardio.2018.1.10083] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
35
|
Abstract
Chronic heart failure is an important global public health problem. This is associated with extremely poor prognosis, high readmission rates, and substantial treatment costs in patients. The paper gives the main aspects of the setting-up of a specialized service to patients with heart failure.
Collapse
Affiliation(s)
- S N Tereshchenko
- A.L. Myasnikov Institute of Cardiology, Russian Cardiology Research and Production Complex, Ministry of Health of the Russian Federation, Moscow, Russia
| | - I V Zhirov
- A.L. Myasnikov Institute of Cardiology, Russian Cardiology Research and Production Complex, Ministry of Health of the Russian Federation, Moscow, Russia
| |
Collapse
|
36
|
Skvortsov AA, Protasov VN, Narusov OY, Koshkina DE, Osmolovskaya YF, Kuznetsova TV, Masenko VP, Tereshchenko SN. Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure Decompensation. CARDIO 2017; 57:20-33. [DOI: 10.18087/cardio.2017.9.10028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2018] [Indexed: 11/18/2022]
|
37
|
Tereshchenko SN, Zhirov IV, Kochetov AG. [Translational medicine in Russian cardiology: a new stage or repetition of the past?]. TERAPEVT ARKH 2016; 88:5-9. [PMID: 27735907 DOI: 10.17116/terarkh20168895-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The brief review gives the experience in using the concept of translational medicine in the practical activities of the Russian Cardiology Research and Production Complex in the past 25 years of its existence. It outlines the possible ways of developing this area in Russian medicine to solve crucial scientific and practical tasks.
Collapse
Affiliation(s)
- S N Tereshchenko
- Russian Cardiology Research and Production Complex, Ministry of Health of Russia, Moscow, Russia
| | - I V Zhirov
- Russian Cardiology Research and Production Complex, Ministry of Health of Russia, Moscow, Russia
| | - A G Kochetov
- Russian Cardiology Research and Production Complex, Ministry of Health of Russia, Moscow, Russia
| |
Collapse
|
38
|
Skvortsov AA, Koshkina DE, Narusov OY, Protasov VN, Masenko VP, Tereshchenko SN. [Therapy of High Risk Patients After Decompensation of Heart Failure Under NT-proBNP Control. Main Results]. Kardiologiia 2016; 56:25-38. [PMID: 28290905 DOI: 10.18565/cardio.2016.7.25-38] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AIM to compare efficacy of treatment of high risk patients after acute decompensation (AD) of chronic heart failure (CHF) based on monitoring of NT-proBNP concentration and standard treatment. MATERIAL AND METHODS Patients (n=100) with class III-IV CHF and left ventricular ejection fraction (LV EF) <40% due to ischemic heart disease (IHD), dilated cardiomyopathy (DCMP), or arterial hypertension (AH) after compensation of HF before discharge were distributed into groups of low (NT-proBNP <1400 picog/ml, n=30) or high (NT-proBNP more or equal 1400 picog/ml, n=70) risk. High risk patients were randomized into 2 treatment groups: NT-proBNP based (group I, n=35) and standard (group II, n=35) therapy. At study closure we formed another group consisting of group I and II participants noncomplaint with study protocol (group NC, n=10). Groups practically did not differ by main clinical functional characteristics. Aim of treatment was lowering of NT-proBNP level below 1000 picog/ml or more or equal 50% from baseline. At discharge median NT-proBNP concentration was 3750.0 (2224.0; 6613.0), 2783.0 (2021.5; 4827.5), and 2162.0 (1684.5; 5750.0) picog/ml in groups I, II, and NC, respectively (=0.315). RESULTS At study entry all group I and II patients received combination of angiotensin converting enzyme inhibitors or angiotensin receptor blockers, -adrenoblockers, antagonists of mineralocorticoid receptors. After 6 months changes of doses of neuro-hormonal modulators in group I were more pronounced than in group II. NT-proBNP concentration decreased by 53% down to 1585.5 (976,6; 2742,5) picog/ml, =0.001, and by 10.2% in groups I and II, respectively (between group =0.001). In group I compared with II we observed more pronounced improvement of clinical functional indicators, quality of life, and parameters of systolic and diastolic LV function (<0.05), fewer cardiovascular deaths (4 vs. 10, =0.033) and repeat decompensations and rehospitalizations because CHF (4 vs. 14, =0.007). CONCLUSION Compared with standard therapy long-term NT-proBNP guided treatment of high risk patients significantly significantly decreased rate of CV deaths and repeat decompensations and rehospitalizations because CHF, and more effectively influenced clinical and functional state, quality of life and main echocardiographical parameters of LV systolic and diastolic function.
Collapse
Affiliation(s)
- A A Skvortsov
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| | - D E Koshkina
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| | - O Yu Narusov
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| | - V N Protasov
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| | - V P Masenko
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| | - S N Tereshchenko
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| |
Collapse
|
39
|
Zhirov IV, Osmolovskaya YF, Tereshchenko SN. [Trimetazidine in the Treatment of Chronic HeartFailure]. Kardiologiia 2016; 56:79-85. [PMID: 28294737 DOI: 10.18565/cardio.2016.1.79-85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The review presents data on alterations of mitochondrial oxidative metabolism occuring due to heart failure, mechanisms of cytoprotective agent trimetazidine associated with a partial inhibition of the fatty acid oxidation and increased metabolism of pyruvate, reduction of cardiomyocyte apoptosis and oxidative stress are described. The results of clinical studies showing the effectiveness of trimetazidine therapy in ischemic heart decease are reported, as well as the latest data on the effects of prolonged use of trimetazidine on prognosis in patients with heart failure.
Collapse
Affiliation(s)
- I V Zhirov
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| | - Yu F Osmolovskaya
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| | - S N Tereshchenko
- Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
| |
Collapse
|
40
|
Petrukhina AA, Tereshchenko SN, Zhirov IV. Modulation of Cardiac Contractility – a New Method in the Treatment of Heart Failure. Racionalʹnaâ farmakoterapiâ v kardiologii 2016. [DOI: 10.20996/1819-6446-2016-12-5-574-581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
41
|
Tereshchenko SN, Zhirov IV, Romanova NV, Osmolovskaya YF, Golitsyn SP. The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Racionalʹnaâ farmakoterapiâ v kardiologii 2015. [DOI: 10.20996/1819-6446-2015-11-6-577-581] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
42
|
Oshchepkova EV, Lazareva NV, Satlykova DF, Tereshchenko SN. [The First Results of the Russian Register of Chronic Heart Failure]. Kardiologiia 2015; 55:22-8. [PMID: 26615620 DOI: 10.18565/cardio.2015.5.22-28] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We present in this paper first results of the Russian registry of chronic heart failure (CHF) as well as comparative analysis of available registries and a number of randomized controlled trials and meta-analyses on CHF.
Collapse
|
43
|
Osmolovskaya YF, Zhirov IV, Tereshchenko SN. [Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015]. TERAPEVT ARKH 2015; 87:77-83. [PMID: 26591557 DOI: 10.17116/terarkh201587977-83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventricular systolic function and the advent and practical introductions of safer new-generation MCRA remain to be answered.
Collapse
Affiliation(s)
- Yu F Osmolovskaya
- Department of Myocardial Diseases and Heart Failure, A.L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Ministry of Health of Russia, Moscow
| | - I V Zhirov
- Department of Myocardial Diseases and Heart Failure, A.L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Ministry of Health of Russia, Moscow
| | - S N Tereshchenko
- Department of Myocardial Diseases and Heart Failure, A.L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Ministry of Health of Russia, Moscow
| |
Collapse
|
44
|
Tereshchenko SN, Zhirov IV, Nasonova SN. [What We Know About Acute Decompensation of Heart Failure?]. Kardiologiia 2015; 55:91-96. [PMID: 28294903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Affiliation(s)
- S N Tereshchenko
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, 15a, Tretiya Cherepkovskaya str., 121552 Moscow, Russia
| | - I V Zhirov
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, 15a, Tretiya Cherepkovskaya str., 121552 Moscow, Russia
| | - S N Nasonova
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, 15a, Tretiya Cherepkovskaya str., 121552 Moscow, Russia
| |
Collapse
|
45
|
Lakomkin SV, Tereshchenko SN, Sychev AV, Masenko VP, G TA, Gerasimova ON, Sigalovich EY, Dankovtseva EN, Zateyshchikov DA. [Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease]. Kardiologiia 2015; 55:37-41. [PMID: 28294809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
We tested possibility of the use of apelin-12 as a biomarker of chronic heart failure (CHF). The study comprised 108 patients with I-IV functional class CHF of various etiology (ischemic heart disease, dilation cardiomyopathy) and 40 healthy volunteers. Blood samples were taken at hospital admission before prescription of pharmacological therapy. In all patients we carried out echocardiography with calculation of end-diastolic and end-systolic volumes (EDV, ESV) and ejection fraction (EF). Blood plasma apelin-12 concentration was compared with CHF market NT-proBNP. Mean apelin-12 concentrations were 0.86+/-0.22 hg/ml in healthy volunteers and 0.8+/-0.35, 0.81+/-0.29, 0.68+/-0.38, 0.82+/-0.35 hg/ml in patients with CHF classes I, II, III, IV, respectively. There was no significant differences between appelin-12 concentrations in various classes of CHF. No correlations were found between apelin-12 and EF, EDV, ESV, sex, age, smoking, body mass index, and NT-proBNP level. Concentration of NT pro-BNP level correlated with CHF severity. Thus apelin-12 did not show itself as reliable biomarker of CHF.
Collapse
Affiliation(s)
- S V Lakomkin
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - S N Tereshchenko
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - A V Sychev
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - V P Masenko
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - Tkachev A G
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - O N Gerasimova
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - E Y Sigalovich
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - E N Dankovtseva
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - D A Zateyshchikov
- Russian Cardiology Research and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| |
Collapse
|
46
|
Tereshchenko SN, Zhirov IV, Nasonova SN. [What We Know About Acute Decompensation of Heart Failure?]. Kardiologiia 2015; 55:91-96. [PMID: 26502509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
47
|
Koshkina LE, Skvortsov AA, Protasov VN, Narusov OI, Tereshchenko SN. [The role of markers of organ damage in patients with chronic heart failure]. Kardiologiia 2015; 55:70-76. [PMID: 26050496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
This review is devoted to the studies of the role of modern markers of myocardial and renal damage (high sensitivity troponin T [hsTnT] and urinary neutrophil gelatinase-associated lipocain [NGA/lipocalin-2] in patients with chronic heart failure (CHF). It contains description of nature, mechanism of synthesis, and release of hsTnT and NGAL, problems of variability of determination of these biomarkers, consideration of causes of elevation of their activity in CHF. Both hsTnT and NGAL have high diagnostic and prognostic significance. Determination of these biomarkers in combination with natriuretic peptides gives complimentary information for more accurate stratification of risk of development of possible complications. Measurement of activity of hsTnT and NGAL (lipocalin-2) will make it easier for a physician to solve the problem of optimization of therapy and management of a concrete patient.
Collapse
|
48
|
Zhirov IV, Romanova NV, Tereshchenko SN, Osmolovskaya YF. [Epidemiology and Management of Heart Failure Patients With Atrial Fibrillation]. Kardiologiia 2015; 55:91-96. [PMID: 26320296 DOI: 10.18565/cardio.2015.3.91-96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The number of patients with heart failure and atrial fibrillation is huge. Population of patients with heart failure in combination with atrial fibrillation is characterized by poor quality of life and adverse outcomes. In this review we summarized data on the guideline adherence and prevalence of long-term anticoagulant therapy in patients with atrial fibrillation and heart failure.
Collapse
|
49
|
Koshkina DE, Skvortsov AA, Protasov VN, Narusov OY, Tereshchenko SN. [The Role of Markers of Organ Damage in Patients With Chronic Heart Failure]. Kardiologiia 2015; 55:70-76. [PMID: 28294832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
This review is devoted to the studies of the role of modern markers of myocardial and renal damage (high sensitivity troponin T [hsTnT] and urinary neutrophil gelatinase-associated lipocain [NGAL/lipocalin-2] in patients with chronic heart failure (CHF). It contains description.
Collapse
Affiliation(s)
- D E Koshkina
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - A A Skvortsov
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - V N Protasov
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - O Yu Narusov
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| | - S N Tereshchenko
- Institute of Cardiology, Russian Cardiology Scientific and Production Complex, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia
| |
Collapse
|
50
|
|